Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Immutep Ltd.
Teva announced the appointment of former Sandoz CEO Richard Francis as its next leader as Kare Schultz steps down.
Clinical stage innovator Immutep talks to In Vivo about the potential for LAG-3 antibodies in cancer and autoimmune diseases.
With a new CEO at the helm, Gamida is closing in on an FDA approval, but a lack of cash could hobble its US launch efforts for allogeneic cell therapy product omidubicel.
Significant change is brewing at Mayne Pharma, with the Australian firm announcing the proposed sale of its US-based CDMO business for nearly half-a-billion dollars. At the same time, long time CEO Scott Richards is heading for the exit door.
- Drug Delivery
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Immutep S.A.S.
- Immutep GmbH
- Immutep, U.S., Inc.
- Prima BioMed Ltd.